



2

4/13  
WBS  
8/18/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ) Art Unit: 1813  
John CLASSEN ) Examiner:  
Serial No.: 08/591,651 ) Washington, D.C.  
Filed: February 12, 1996 ) July 23, 1997  
For: METHOD AND COMPOSITION ) Docket No.: CLASSEN=1A  
FOR AN EARLY VACCINE... )

SECOND PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Prior to action on the case, please enter the following amendments:

IN THE CLAIMS

Please add the following new claims:

*C* C *B* *B* *Confidential* *F* F  
--34. The kit of claim 25, where said kit is to be used  
to reduce the incidence or severity of an autoimmune disease,  
and said labeling so indicates and provides instruction for  
such use. *27*

35. The kit of claim 25 wherein said labeling states  
that said kit is to be used to reduce the incidence or  
severity of systemic lupus *erythematosus*, and provides  
instruction for such use. *43*

36. The kit of claim 27, at least one of said immunogens  
also acting to substantially reduce the incidence or severity  
of an infectious disease to which said mammal is susceptible,  
and said labeling so indicates, and provides instruction for  
such use. *43*

*F* 37. The kit of claim 27, which includes at least one  
immunogen other than a BCG, diphtheria, tetanus, pertussis,  
polio, hepatitis A, hepatitis B, hemophilus influenza,  
measles, mumps and rubella, influenza, cholera, BCG, plague,  
pneumococcus, neisseria, varicella, rabies, typhoid and yellow  
fever immunogen is administered. *43*